MyFinsight
Home
Blog
About
Contact
Thereafter
$65,232K
2030
$5,544K
2029
$5,544K
2028
$5,544K
2027
$5,544K
2026
$4,158K
Thereafter
$6,822K
2030
$1,463K
2029
$1,463K
2028
$1,463K
2027
$1,463K
2026
$1,097K
Thereafter
$5,295K
2030
$941K
2029
$941K
2028
$941K
2027
$941K
2026
$706K
Marketable securities
$148,276K
Accounts receivable, net
$56,879K
Cash and cash
equivalents
$54,034K
Prepaid expenses and
other current assets
$32,281K
Inventory
$1,699K
PONVORY
$91,566K
Hetlioz
$13,771K
NEREUS
$9,765K
Total current assets
$293,169K
Intangible assets, net
$115,102K
Non-current inventory and
other
$11,189K
Finance lease
right-of-use assets
$7,284K
Operating lease
right-of-use assets
$4,536K
Property and equipment,
net
$2,245K
Total assets
$433,525K
Total liabilities and
stockholders equity
$433,525K
Total stockholders
equity
$280,765K
Total liabilities
$152,760K
Accumulated deficit
-$443,333K
Additional paid-in capital
$723,826K
Total current
liabilities
$135,582K
Other non-current
liabilities
$10,127K
Finance lease
non-current liabilities
$3,785K
Operating lease
non-current liabilities
$3,266K
Accumulated other
comprehensive income
$212K
Common stock, 0.001 par
value 150,000,000...
$60K
Product revenue
allowances
$74,962K
Accounts payable and
accrued liabilities
$60,620K
Back
Back
Balance Sheet
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)
source: myfinsight.com